Detalles de la búsqueda
1.
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
BMC Cancer
; 21(1): 34, 2021 Jan 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33413212
2.
The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results.
J Bone Miner Metab
; 39(2): 224-229, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32889575
3.
[A Case of Synchronous Bilateral Male Breast Cancer].
Gan To Kagaku Ryoho
; 47(6): 973-976, 2020 Jun.
Artículo
en Japonés
| MEDLINE | ID: mdl-32541177
4.
Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
J Bone Miner Metab
; 37(2): 301-306, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29520506
5.
Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
J Bone Miner Metab
; 37(5): 864-870, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30868270
6.
Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis.
Support Care Cancer
; 27(7): 2673-2677, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30478672
7.
[A Case of Breast Cancer with Parenchymal and Meningeal Central Nervous System Metastases Treated with Multimodality Therapy].
Gan To Kagaku Ryoho
; 46(3): 463-465, 2019 Mar.
Artículo
en Japonés
| MEDLINE | ID: mdl-30914585
8.
[A Case of Small Cell Carcinoma of the Breast].
Gan To Kagaku Ryoho
; 46(12): 1891-1893, 2019 Dec.
Artículo
en Japonés
| MEDLINE | ID: mdl-31879410
9.
Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
J Bone Miner Metab
; 36(6): 716-722, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29116414
10.
[A Case of Bone Marrow Carcinomatosis of Occult Breast Cancer Treated Effectively with Fulvestrant].
Gan To Kagaku Ryoho
; 45(9): 1381-1384, 2018 Sep.
Artículo
en Japonés
| MEDLINE | ID: mdl-30237387
11.
[Experience of Fulvestrant for Hormone Receptor-Positive HER2-Negative Advanced and Metastatic Breast Cancer].
Gan To Kagaku Ryoho
; 45(6): 949-954, 2018 Jun.
Artículo
en Japonés
| MEDLINE | ID: mdl-30026420
12.
[A case of stage IV breast cancer with long-term partial response treated with tri-weekly paclitaxel plus bevacizumab].
Gan To Kagaku Ryoho
; 42(3): 343-6, 2015 Mar.
Artículo
en Japonés
| MEDLINE | ID: mdl-25812504
13.
The Feasibility of Omission of Postoperative Radiotherapy in Japanese Patients With Early Breast Cancer Treated With Breast-Conserving Surgery.
Cureus
; 16(5): e60228, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38872705
14.
Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence.
Ann Surg Oncol
; 20(6): 1886-92, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23292516
15.
Myoid hamartoma of the breast that proved difficult to diagnose: a case report.
World J Surg Oncol
; 10: 12, 2012 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-22248347
16.
[A case of metastatic pancreatic cancer which trastuzumab+capecitabine combination therapy was effective].
Gan To Kagaku Ryoho
; 39(8): 1243-5, 2012 Aug.
Artículo
en Japonés
| MEDLINE | ID: mdl-22902450
17.
[A case of breast cancer with brain metastases responding to paclitaxel and capecitabine therapy].
Gan To Kagaku Ryoho
; 39(2): 261-3, 2012 Feb.
Artículo
en Japonés
| MEDLINE | ID: mdl-22333639
18.
[Administration of nab-paclitaxel for 9 metastatic breast cancer patients].
Gan To Kagaku Ryoho
; 39(7): 1081-5, 2012 Jul.
Artículo
en Japonés
| MEDLINE | ID: mdl-22790043
19.
[A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].
Gan To Kagaku Ryoho
; 39(11): 1699-702, 2012 Nov.
Artículo
en Japonés
| MEDLINE | ID: mdl-23152022
20.
Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.
Breast Cancer
; 29(5): 796-807, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35460066